SecBot SecBot
SECBOTREPLAY Home › Report › PEPG

PEPG · PepGen reported financial results for 2025 and provided updates on its…

PepGen Inc. · 8-K filed Mar 4, 2026 at 16:11 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 4, 2026 at 16:11 ET

PepGen reported financial results for 2025 and provided updates on its PGN-EDODM1 clinical program for myotonic dystrophy type 1. The company announced a partial clinical hold by the FDA on its FREEDOM2 trial due to preclinical pharmacology and toxicology concerns, while also highlighting positive Phase 1 data and ongoing enrollment in international sites. Financially, the company reduced its net loss year-over-year and maintains a strong cash position into 2027.

  • FDA placed a partial clinical hold on the FREEDOM2 Phase 2 trial due to preclinical pharmacology and toxicology data concerns
  • Positive Phase 1 FREEDOM trial data showed dose-dependent splicing correction up to 53.7% at 15 mg/kg with generally well-tolerated safety profile
  • Company expects data readouts from the 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in 2H 2026
  • Cash position of $148.5 million as of December 31, 2025, sufficient to fund operations into the second half of 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access